AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Scienture Holdings shares surge 11.81% intraday following FDA-approved REZENOPY® naloxone nasal spray launch and U.S. commercialization plans.
ByAinvest
Tuesday, Dec 23, 2025 11:41 am ET1min read
SCNX--
Scienture Holdings surged 11.81% in intraday trading following the announcement of its high-strength REZENOPY® naloxone HCl nasal spray's commercial launch. The FDA-approved product, developed under an exclusive agreement with Summit Biosciences, is set for wholesale distribution in Q1 2026 and market availability by early Q2 2026. This expansion into opioid overdose treatments underscores the company’s strategic focus on addressing a critical U.S. healthcare need, positioning REZENOPY as a high-potential therapeutic option in a growing market. The news directly aligns with the stock’s upward movement, reflecting investor optimism over the product’s commercial viability and market impact.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet